Pharmacologic Disruption: How Emerging Weight Loss Therapies Are Challenging Bariatric Surgery Guidelines. [PDF]
Medicina (Kaunas)Alqatari SG +5 more
europepmc +1 more source
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity [PDF]
New England Journal of MedicineSemaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg has shown promising results in early-phase trials; the efficacy of the combination (known as CagriSema) on weight loss in persons with either overweight and coexisting conditions or obesity is unknown.In a phase 3a, 68-week ...
Garvey, W. Timothy +199 more
exaly +5 more sources
Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity [PDF]
Cardiology in Review, 2023 Despite the worldwide epidemic of obesity, there remain few approved pharmacological treatment options to bridge the gap between lifestyle therapy and bariatric surgery. Cagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity. Amylin,
Antonella M, D'Ascanio +2 more
openaire +3 more sources
Related searches:
Cagrilintide–Semaglutide in Adults with Overweight or Obesity
New England Journal of MedicineIn the REDEFINE 1 trial, Garvey and colleagues (Aug. 14 issue)1 report the efficacy of combination therapy with cagrilintide and semaglutide (known as CagriSema) in patients with overweight or obesity who did not have diabetes. The authors acknowledge the predominance of female participants as a limitation.
Hao, Chi, Hua, Yang, Youping, Deng
exaly +7 more sources
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial [PDF]
Lancet, The, 2023 BACKGROUND: Combining the GLP-1 receptor agonist semaglutide with the long-acting amylin analogue cagrilintide has weight-loss benefits; the impact on glycated haemoglobin (HbA1c) is unknown. This trial assessed the efficacy and safety of co-administered
Ildikó Lingvay +2 more
exaly +8 more sources
Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
New England Journal of MedicineCagrilintide and semaglutide have each been shown to induce weight loss as monotherapies. Data are needed on the coadministration of cagrilintide and semaglutide (called CagriSema) for weight management in adults with type 2 diabetes, including those in a subgroup who are undergoing continuous glucose monitoring.In this phase 3a, double-blind ...
Carel Le Roux +2 more
exaly +3 more sources
<p>The escalating global burden of obesity and type 2 diabetes (T2D) necessitates highly effective therapies. The novel fixed-dose combination Cagrilintide-Semaglutide (CagriSema), merging a GLP-1 receptor agonist (Semaglutide) with an amylin analog (Cagrilintide), represents a significant therapeutic advance.
Zhien Feng
exaly +2 more sources
GIM/FP/GP: [Formula: see text].
Arnav Agarwal, Raj Padwal
exaly +3 more sources
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial [PDF]
Lancet, The, 2021 BACKGROUND: Natural amylin is a pancreatic hormone that induces satiety. Cagrilintide is a long-acting amylin analogue under investigation for weight management.
Carel Le Roux +2 more
exaly +2 more sources
Exploration of Cagrilintide's Mechanism of Action in the Kidneys
Journal of the American Society of Nephrology: JASNSagar Bhayana, Mette Viberg Østergaard
exaly +2 more sources